Media Launch
COPENHAGEN, Denmark; March 1, 2022
Genmab A/S (Nasdaq: GMAB) introduced at the moment that Birgitte Stephensen has been appointed to Chief Authorized Officer and Chris Cozic has been appointed to Chief Folks Officer throughout the Genmab Govt Administration Staff and promoted to Govt Vice Presidents efficient March 1, 2022. Birgitte Stephensen joined Genmab in 2002 and beforehand served as Genmab’s Senior Vice President, Mental Property Rights and Authorized. Chris Cozic joined Genmab in 2017 and most just lately served as Senior Vice President International Human Assets. Birgitte and Chris each serve on the Govt Administration Staff with Genmab’s President and Chief Govt Officer Dr. Jan van de Winkel, Chief Growth Officer Dr. Judith Klimovsky, Chief Monetary Officer Anthony Pagano, Chief Medical Officer Dr. Tahi Ahmadi, and Chief Working Officer Anthony Mancini.
Primarily based in Genmab’s headquarters in Copenhagen, Denmark, Birgitte has in depth expertise from each personal follow and trade working with mental property and authorized issues throughout the pharmaceutical and biotech discipline. In her tenure at Genmab, she has been instrumental in main the corporate’s mental property rights and authorized technique. Birgitte handed the European Qualifying Examination as European Patent Legal professional. She earned a Grasp of Science from the Danish College of Pharmaceutical Sciences.
Primarily based in Genmab’s Princeton, U.S. workplace, Chris has in depth expertise as a worldwide human useful resource government in strategic management, group design, human useful resource administration, coverage improvement, worker relations, organizational improvement, and a heavy focus in all points of company development and enlargement. Previous to becoming a member of Genmab, he held management roles within the biopharma and telecommunications industries. Chris obtained his bachelor’s diploma in English and Communications from Quinnipiac College and likewise attained Senior and International Skilled Human Useful resource (SPHR and GPHR) certifications.
“Genmab is on an thrilling journey in the direction of changing into an built-in biotech innovation powerhouse bringing our personal progressive medicines to sufferers. We’ve a world-class Govt Administration Staff and each Birgitte and Chris’ appointments additional strengthen and elevate the crucial work of their teams for our firm,” mentioned Jan van de Winkel, Ph.D., Chief Govt Officer of Genmab.
About Genmab
Genmab is a world biotechnology firm with a core function to enhance the lives of individuals with most cancers. For greater than 20 years, Genmab’s imaginative and prescient to rework most cancers therapy has pushed its passionate, progressive and collaborative groups to invent next-generation antibody expertise platforms and leverage translational analysis and information sciences, fueling a number of differentiated most cancers therapies that make an affect on folks’s lives. To develop and ship novel therapies to sufferers, Genmab has shaped 20+ strategic partnerships with biotechnology and pharmaceutical corporations. Genmab’s proprietary pipeline contains bispecific T-cell engagers, next-generation immune checkpoint modulators, effector operate enhanced antibodies and antibody-drug conjugates.
Genmab is headquartered in Copenhagen, Denmark with areas in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan. For extra info, please go to Genmab.com and observe us on Twitter.com/Genmab.
Contact:
Marisol Peron, Senior Vice President, International Investor Relations & Communications
T: +1 609 524 0065; E: mmp@genmab.com
For Investor Relations:
Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com
This Media Launch accommodates ahead trying statements. The phrases “imagine”, “anticipate”, “anticipate”, “intend” and “plan” and comparable expressions determine ahead trying statements. Precise outcomes or efficiency could differ materially from any future outcomes or efficiency expressed or implied by such statements. The necessary elements that would trigger our precise outcomes or efficiency to vary materially embody, amongst others, dangers related to pre-clinical and scientific improvement of merchandise, uncertainties associated to the end result and conduct of scientific trials together with unexpected issues of safety, uncertainties associated to product manufacturing, the dearth of market acceptance of our merchandise, our incapacity to handle development, the aggressive atmosphere in relation to our enterprise space and markets, our incapacity to draw and retain suitably certified personnel, the unenforceability or lack of safety of our patents and proprietary rights, {our relationships} with affiliated entities, adjustments and developments in expertise which can render our merchandise or applied sciences out of date, and different elements. For an extra dialogue of those dangers, please consult with the chance administration sections in Genmab’s most up-to-date monetary reviews, which can be found on www.genmab.com and the chance elements included in Genmab’s most up-to-date Annual Report on Kind 20-F and different filings with the U.S. Securities and Alternate Fee (SEC), which can be found at www.sec.gov. Genmab doesn’t undertake any obligation to replace or revise ahead trying statements on this Media Launch nor to verify such statements to mirror subsequent occasions or circumstances after the date made or in relation to precise outcomes, until required by legislation.
Genmab A/S and/or its subsidiaries personal the next emblems: Genmab®; the Y-shaped Genmab emblem®; Genmab together with the Y-shaped Genmab emblem®; HuMax®; DuoBody®; DuoBody together with the DuoBody emblem®; HexaBody®; HexaBody together with the HexaBody emblem®; DuoHexaBody® and HexElect®.
Media Launch no. 05
CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122
Genmab A/S
Kalvebod Brygge 43
1560 Copenhagen V
Denmark
Attachment
